PRME
NASDAQ
$3.05
Prime Medicine Inc (PRME)
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.12 (+133.44%)
Market Cap
$630M
Free Cash Flow Yield
-25.18%
Beta (5Y)
2.09
Price Chart
Valuation
Market Cap$630M
P/S156.26
P/B8.16
Profitability
Total Revenue (TTM)$3.18M
Gross Profit (TTM)-$150M
EBITDA-$199M
Operating Margin-5918%
EPS-$1.20
Financial Health
Free Cash Flow Yield-25.18%
Growth & Risk
Beta (5Y)2.09
Sharpe Ratio0.13